Shared decision making in patients with Castration-Resistant Prostate Cancer

Recruiting

• Conditions: Shared decision making, decision aid, prostate cancer, CRPC

• Registration Number: NL-OMON24989
• Lead Sponsor: Elisabeth- TweeSteden ZiekenhuisPostbus 901515000 LC Tilburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 168

Inclusion Criteria

Men that are newly diagnosed with CRPC. CRPC is defined as any cancer progression under maximal hormonal treatment with anti-androgens and/or LHRH agonist or antagonist (when three consecutive rises of PSA are observed at castrate serum levels of testosterone (< 50 ng/dL or <1.7 nmol/L) and/or progression of osseous lesions is shown))

- Patients are eligible for at least two treatment options

Exclusion Criteria

- In the case of a second opinion the patient will not be included if the first opinion was obtained in one of the other involved hospitals and vice versa

- Patients who do not have sufficient knowledge of the Dutch language

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
- Objective knowledge<br /><br>- Informed choice

Secondary Outcome Measures

Name	Time	Method
- Correlation between G8 score and treatment decision<br /><br>- Correlation between TUG-test and treatment decision <br /><br>- Quality of life <br /><br>- Anxiety <br /><br>- Value clarification<br /><br>- Satisfaction with decision making, information and treatment<br /><br>- Preparation for decision making <br /><br>- Healthcare providers' evaluation of decision aid <br /><br>- Partner involvement in SDM<br /><br>- Treatment outcome (e.g. dose reductions, treatment delays, treatment discontinuation, treatment switch, and death)